Literature DB >> 25812115

CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial.

D Wildner1, T Bernatik2, C Greis3, K Seitz4, M F Neurath1, D Strobel1.   

Abstract

PURPOSE: The aim of the study was the comparison of tumor vascularization and contrast enhancement in contrast-enhanced ultrasound (CEUS) for the characterization of hepatocellular carcinoma (HCC) and intrahepatic cholangiocellular carcinoma (ICC). We present data of the subpopulations HCC and ICC examined in the DEGUM multicenter trial for the characterization of focal liver lesions in clinical practice.
MATERIALS AND METHODS: Based on the data of the DEGUM multicenter trial (1349 patients), all patients with histologically proven HCC (n = 278) and ICC (n = 42) were analyzed. The vascularity pattern and contrast enhancement pattern during the arterial, portal-venous and late phase were compared.
RESULTS: An underlying liver cirrhosis was found in 214/278 patients with HCC (76.9 %) and 7/42 patients with ICC (16.7 %). In CEUS, HCC showed a global arterial hyperenhancement compared to ICC (HCC: tumor center: 60.3 %; tumor periphery: 75 %; ICC: tumor center: 16.7 %; tumor periphery: 40.5 %). ICC showed an initial contrast enhancement primarily at the tumor periphery (ICC: 85.7 % vs. HCC: 61 %) followed by an early portal-venous contrast washout in the tumor center (ICC: 85.8 % vs. HCC: 49.8 %) and tumor periphery (ICC: 66.7 % vs. HCC: 32.6 %). HCC showed a delayed contrast washout (late phase hypoenhancement: HCC: 75 % vs. ICC: 92.9 %).
CONCLUSION: ICCs are rare in cirrhotic livers. CEUS can demonstrate differences in the vascularization patterns between HCC and ICC. HCC showed an arterial global hyperenhancement and delayed contrast washout in the late phase. ICCs are characterized by an arterial contrast enhancement at the tumor periphery with early contrast washout of the vascularized parts of the lesions in the portal-venous and late phase. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25812115     DOI: 10.1055/s-0034-1399147

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  35 in total

Review 1.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 3.  Using LI-RADS With Contrast-Enhanced Ultrasound.

Authors:  Shuchi K Rodgers; David T Fetzer; Yuko Kono
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

5.  Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.

Authors:  Li-Da Chen; Si-Min Ruan; Yuan Lin; Jin-Yu Liang; Shun-Li Shen; Hang-Tong Hu; Yang Huang; Wei Li; Zhu Wang; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Wei Wang
Journal:  Eur Radiol       Date:  2018-12-19       Impact factor: 5.315

6.  Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.

Authors:  Barbara Schellhaas; Matthias Hammon; Deike Strobel; Lukas Pfeifer; Christian Kielisch; Ruediger S Goertz; Alexander Cavallaro; Rolf Janka; Markus F Neurath; Michael Uder; Hannes Seuss
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

7.  Accuracy of Contrast-Enhanced Ultrasound in the Diagnosis of Bile Duct Obstruction.

Authors:  F J P Fontán; Á R Reboredo; A R Siso
Journal:  Ultrasound Int Open       Date:  2015-07

8.  Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group.

Authors:  Andrej Lyshchik; Yuko Kono; Christoph F Dietrich; Hyun-Jung Jang; Tae Kyoung Kim; Fabio Piscaglia; Alexander Vezeridis; Juergen K Willmann; Stephanie R Wilson
Journal:  Abdom Radiol (NY)       Date:  2018-04

Review 9.  CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together?

Authors:  Cosmin Caraiani; Bianca Boca; Vlad Bura; Zeno Sparchez; Yi Dong; Christoph Dietrich
Journal:  Biology (Basel)       Date:  2021-05-06

10.  Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma.

Authors:  Feiqian Wang; Kazushi Numata; Masahiro Okada; Makoto Chuma; Hiromi Nihonmatsu; Satoshi Moriya; Akito Nozaki; Katsuaki Ogushi; Wen Luo; Litao Ruan; Masayuki Nakano; Masako Otani; Yoshiaki Inayama; Shin Maeda
Journal:  Quant Imaging Med Surg       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.